OncoMatch/Clinical Trials/NCT04614103
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Is NCT04614103 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including LN-145 and LN-145 for metastatic non small cell lung cancer.
Treatment: LN-145 · LN-145 — This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: immune checkpoint inhibitor — first-line
documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy ± bevacizumab
Must have received: platinum-based chemotherapy — first-line
documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy ± bevacizumab
Cannot have received: cell therapy
prior cell therapy within the past 20 years
Cannot have received: allogeneic organ transplant
allogeneic organ transplant
Lab requirements
Cardiac function
lvef > 45%, nyha class 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UC San Diego Moores Cancer Center · La Jolla, California
- University of Southern California · Los Angeles, California
- Christiana Care Health System · Newark, Delaware
- University of Florida Health Cancer Center · Gainesville, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04614103 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cell therapy, allogeneic organ transplant disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages